Abstract
Discovery of melanoma-targeting antibodies using a proteome-scale array and use of a cutting-edge linker-payload system led to development of a MUC18-targeting antibody-exatecan conjugate with clinical potential for treating major melanoma subtypes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have